Amolimogene

Generic Name
Amolimogene
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
676269-70-8
Unique Ingredient Identifier
8B5KCA0GAK
Background

Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

Indication

Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).

Associated Conditions
-
Associated Therapies
-

A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-12-13
Last Posted Date
2013-05-29
Lead Sponsor
Eisai Inc.
Target Recruit Count
251
Registration Number
NCT00264732
Locations
🇺🇸

Physician Care Clinical Research, Sarasota, Florida, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

Visions Clinical Research, Boynton Beach, Florida, United States

and more 23 locations
© Copyright 2024. All Rights Reserved by MedPath